Lipid-Based Solutions to Improve Bioavailability at Drug Delivery Congress
Dr. Plassat’s session, on Monday 18th at 9.30 a.m., is entitled “Accelerating the development of compounds with bioavailability limitations,†and will discuss the development of orally-delivered, lipid-based systems that can be used to improve the bioavailability of New Chemical Entities which offer therapeutic promise for patients, but exhibit limiting physico-chemical attributes for conventional, solid oral dose delivery.
Dr. Plassat joined 91Ï㽶ÊÓƵ in 2013, initially as a formulation scientist, drawing upon his experience in lipid-based softgel development for the oral delivery of macromolecules, before becoming Scientific Affairs Manager. Prior to joining 91Ï㽶ÊÓƵ, he worked at OTR3, a Paris-based startup company, developing targeted therapies.
Dr. Plassat is a pharmacist, and received a Ph.D. from the University of Paris Sud in Pharmaceutical Technologies.
About 91Ï㽶ÊÓƵ
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs approximately 8,000 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, N.J. For more information, visit www.catalent.com